The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review

Christelle de la Fouchardiere; Abir Alghuzlan; Stéphane Bardet; Isabelle Borget; Françoise Borson Chazot; Christine Do Cao; Yann Godbert; Laurence Leenhardt; Slimane Zerdoud; Sophie Leboulleux

doi:10.1016/j.bulcan.2019.04.012

The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF^® network review

Bull Cancer. 2019 Sep;106(9):812-819. doi: 10.1016/j.bulcan.2019.04.012. Epub 2019 Jun 11.

Affiliations

¹ Centre Léon-Berard, 28, rue Laennec, 69008 Lyon, France. Electronic address: Christelle.delafouchardiere@lyon.unicancer.fr.
² Pathology department, Gustave-Roussy, 94800 Villejuif, France.
³ Centre François-Baclesse, department of nuclear medicine and thyroid unit, 14076 Caen, France.
⁴ Department of biostatistic and epidemiology, Gustave-Roussy, Villejuif, France.
⁵ Hospices civils de Lyon, hôpital Louis-Pradel, endocrinology department, 69500 Bron, France.
⁶ Centre hospitalier régional universitaire de Lille, 59000 Lille, France.
⁷ Institut Bergonié, nuclear medicine department, 30003 Bordeaux, France.
⁸ Pitié-Salpêtrière hospital, Sorbonne university, department of thyroid and endocrine tumours, 75013 Paris, France.
⁹ Claudius-Regaud institute, oncology university institute-IUCT-oncopole, department of nuclear medicine, 31100 Toulouse, France.
¹⁰ Department of nuclear medicine and endocrine tumors, Gustave-Roussy, Villejuif, France.

PMID: 31200896
DOI: 10.1016/j.bulcan.2019.04.012

Abstract

Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC.

Keywords: Antiangiogenic; Molecular biology; Network; Radioiodine-refractory differentiated thyroid carcinoma; TUTHYREF; Target therapy.

Publication types

Review

MeSH terms

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use*
Humans
Immunotherapy
Iodine Radioisotopes / therapeutic use*
Middle Aged
Network Meta-Analysis
Phenylurea Compounds / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Quinolines / therapeutic use
Radiation Tolerance*
Sorafenib / therapeutic use
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / mortality
Thyroid Neoplasms / pathology
Thyroid Neoplasms / radiotherapy*

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Iodine Radioisotopes
Phenylurea Compounds
Protein Kinase Inhibitors
Quinolines
Sorafenib
lenvatinib